Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News MindBio Therapeutics Corp C.MBIO

Healthcare Biotechnology
MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:MBIO)

MindBio Therapeutics Enrols 25th Participant into Landmark Take-Home Microdosing Depression Trial

TheNewsWire 6 days ago

MindBio advances world-first psychedelic microdosing clinical trials

Jonathon Brown August 29, 2024

MindBio CEO Provides Video Update to Shareholders on Progress of World First, Government Approved Microdosing Clinical Trials

TheNewsWire August 29, 2024

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials

Accesswire August 19, 2024

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

Accesswire August 1, 2024

Mindbio Therapeutics CEO Issues Letter To Shareholders

Accesswire July 8, 2024

MindBio's microdosed LSD reduces depression post treatment

Trevor Abes  June 20, 2024

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Accesswire June 20, 2024

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

Accesswire June 12, 2024
View More News ››

Opinion & Analysis (CSE:MBIO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (CSE:MBIO)

MindBio's microdosed LSD reduces depression post treatment

https://stockhouse.com/news/the-market-online-news/2024/06/20/mindbio-s-microdosed-lsd-reduces-depression-post-treatment
TrevorAbes - June 20, 2024

RE:Enveric

Subsequent to this Enveric received the following notification: https://www.sec.gov/ix?doc=/Archives/edgar/data/890821...
Smokey1958 - May 26, 2024

Enveric

Here is the first document, Form 8-K, that Enveric had to submit to avoid immediate de-listing. They have complied, to no surprise, and...
Smokey1958 - May 26, 2024

RE:RE:RE:Enveric doesn’t meet Nasdaq listing requirements

Here is the website on the process for delisting.  https://waterfrontonline.blog/wp-content/uploads/2022/10/delistingrules.pdf
Smokey1958 - May 26, 2024

RE:RE:Enveric doesn’t meet Nasdaq listing requirements

Make sure you don't cherry pick only that which supports your point of view??? The following is part of the overview of delisting as...
Smokey1958 - May 26, 2024

RE:Enveric doesn’t meet Nasdaq listing requirements

Plus they have NO cash and a HUGE debt. complete bust
MrForthright - May 25, 2024
View more Bullboard ››

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical ...
View More »